It's a risk that Big Pharma has left to little pharma.
And it's not just Benitec.
Big Pharma is quite prepared to pay up rather than see their reputations suffer a failure.
Our next two clinical targets, NSCLC and the ARMD are a very good second and third choice especially if we fail to 'deliver to the liver'.
eye diseases and ddrnai, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)